A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery

This study will evaluate the effects of Parlay Recover peptide gummies (containing Body Protection Compound BPC-157) on markers of inflammation, physical performance, and recovery in physically active adults. Over an 8-week period, 40 participants will consume two gummies daily and complete questionnaires at Baseline, Week 2, Week 4, Week 6, and Week 8, as well as undergo blood testing at Baseline and Week 8.

The primary objective is to examine changes in inflammatory biomarkers (hs-CRP and IL-6) as measured by blood testing. Secondary objectives include evaluating participants' self-reported perceptions of the product's effects on physical performance and recovery, including aching, stiffness, function, and recovery of muscles and joints.

Study Overview

• Status: Completed
• Conditions: Musculoskeletal Pain; Exercise-Induced Muscle Damage; Post-Exercise Recovery; Musculoskeletal Inflammation
• Intervention / Treatment: Dietary supplement: Parlay Recover Peptide Gummies

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89101
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be male or female.
• Be aged 18-65.
• Engages in structured physical activity ≥3 times per week, with each session lasting at least 30 minutes, over the past 3 months (e.g., running, gym/strength training, cycling, team sports, fitness classes).
• Within the last 4 weeks, reports post-exercise musculoskeletal symptoms (aching, stiffness, or delayed recovery) at least once per week.
• Willing to maintain current exercise routine throughout the 8-week study (no major changes in frequency, intensity, or new training programs).
• Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
• If taking products or supplements that target muscle and joint health, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration.
• Willing to maintain the same diet and sleep schedule throughout the study duration.
• Resides in the United States.

Exclusion Criteria:

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
• Use of specialized recovery modalities (e.g., cryotherapy, frequent sports massage, IV nutrition, high-dose recovery supplements) started within the past 8 weeks or expected to be initiated during the trial.
• Acute illness or infection within 14 days prior to Baseline (e.g., fever, flu, COVID-19) or planned surgery during the study.
• History of inflammatory or autoimmune conditions, including but not limited to rheumatoid arthritis, lupus, inflammatory bowel disease (IBD), ankylosing spondylitis, Hashimoto's thyroiditis, or Grave's disease.
• Use of systemic corticosteroids (such as prednisone) within past 8 weeks.
• Recent intra-articular steroid injection within 12 weeks.
• Anyone with any allergies or sensitivities to any of the study product ingredients.
• Anyone who is a heavy drinker (i.e. 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
• Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
• Anyone with uncontrolled chronic diseases, including but not limited to hypertension (high blood pressure) and diabetes.
• Anyone unwilling to follow the study protocol.
• Anyone with nut sensitivity or allergy.
• Anyone with a history of substance abuse.
• Musculoskeletal injury within the past 8 weeks that required any type of modification in your exercise routine.
• Planning on introducing any new products, prescription medications, or supplements that target muscle health, joint health, or exercise performance for the study duration.
• Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.
• Anyone with a history of hypotension.
• Anyone who is currently taking antihypertensive medication.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Parlay Recover Peptide Gummies	Dietary supplement: Parlay Recover Peptide Gummies; All participants receive Parlay Recover peptide gummies containing Body Protection Compound (BPC)-157 (500 µg per serving).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in High-Sensitivity C-Reactive Protein (hs-CRP)	Change in serum hs-CRP levels as measured by blood testing at Quest Diagnostics Clinic	Baseline and Week 8
Change in Interleukin-6 (IL-6)	Change in serum IL-6 levels as measured by blood testing at Quest Diagnostics Clinic	Baseline and Week 8
Change in Self-Reported Swelling	Change in perceived swelling around muscles and joints as assessed by self-reported questionnaire	Baseline, Week 2, Week 4, Week 6, and Week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Self-Reported Aching	Change in perceived aching of muscles and joints as assessed by self-reported questionnaire	Baseline, Week 2, Week 4, Week 6, and Week 8
Change in Self-Reported Stiffness	Change in perceived stiffness of muscles and joints as assessed by self-reported questionnaire	Baseline, Week 2, Week 4, Week 6, and Week 8
Change in Self-Reported Muscle Function	Change in perceived function of muscles as assessed by self-reported questionnaire	Baseline, Week 2, Week 4, Week 6, and Week 8
Change in Self-Reported Recovery	Change in perceived recovery of muscles and joints following physical activity as assessed by self-reported questionnaire	Baseline, Week 2, Week 4, Week 6, and Week 8

Collaborators and Investigators

• Sponsor: Parlay Wellness
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2025
• Primary Completion (Actual): November 1, 2025
• Study Completion (Actual): November 1, 2025

Study Registration Dates

• First Submitted: August 3, 2026
• First Submitted That Met QC Criteria: August 3, 2026
• First Posted (Actual): August 7, 2026

Study Record Updates

• Last Update Posted (Actual): August 7, 2026
• Last Update Submitted That Met QC Criteria: August 3, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Musculoskeletal Pain
• Other Study ID Numbers: 20819 (Fred Hutch/University of Washington Cancer Consortium); legacy-20819

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No